Resveratrol supplementation in schizophrenia patients: A randomized clinical trial evaluating serum glucose and cardiovascular risk factors

Nutrients

Volumn 8, Issue 2, 2016, Pages

  Zortea, Karine ^a,b   Franco, Viviane C ^a,b   Francesconi, Lenise P ^a,b   Cereser, Keila M M ^a,b   Lobato, Maria Inês R ^a,b   Belmonte De Abreu, Paulo S ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cardiovascular disease; Cholesterol; Resveratrol; Schizophrenia

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; TRIACYLGLYCEROL; ANTIOXIDANT; GLUCOSE BLOOD LEVEL; PLANT EXTRACT; STILBENE DERIVATIVE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HUMAN; LIPID ANALYSIS; MALE; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; AGED; BLOOD; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENT; GLUCOSE BLOOD LEVEL; METABOLISM; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; ANTIOXIDANTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; RISK FACTORS; SCHIZOPHRENIA; STILBENES; TRIGLYCERIDES; YOUNG ADULT;

EID: 84957109879     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8020073     Document Type: Article

References (23)

1. Hjorth, P.; Davidsen, A.S.; Kilian, R.; Skrubbeltrang, C. A systematic review of controlled interventions to reduce overweight and obesity in people with schizophrenia. Acta Psychiatr. Scand. 2014, 130, 279-289. [CrossRef] [PubMed]
2. Henderson, D.C.; Nguyen, D.D.; Copeland, P.M.; Hayden, D.L.; Borba, C.P.; Louie, P.M.; Freudenreich, O.; Evins, A.E.; Cather, C.; Goff, D.C. Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risks and mortality: Results of a 10-year naturalistic study. J. Clin. Psychiatry 2005, 66, 1116-1121. [CrossRef] [PubMed]
3. Elkis, H.; Gama, C.S.; Suplicy, H.; Tambascia, M.; Bressan, R.; Lyra, R.; Cavalcante, S.; Minicucci, W. Brazilian Consensus on second-generation antipsychotics and metabolic disorders. Rev. Bras. Psiquiatr. 2008, 30, 77-85. [CrossRef] [PubMed]
4. Bresee, L.C.; Majumdar, S.R.; Patten, S.B.; Johnson, J.A. Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. Eur. Psychiatry 2011, 26, 327-332. [CrossRef] [PubMed]
5. Zortea, K.; Bock, P.M.; Moreno, D.B.; Belmonte-De-Abreu, P.S. Anthropometric and biochemical assessment of schizophrenic patients taking clozapine. Rev. Nutr. Camp. 2009, 22, 697-705.
6. Bakker, G.C.; van Erk, M.J.; Pellis, L.; Wopereis, S.; Rubingh, C.M.; Cnubben, N.H.; Kooistra, T.; van Ommen, B.; Hendriks, H.F. An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: A nutrigenomics approach. Am. J. Clin. Nutr. 2010, 91, 1044-1059. [CrossRef] [PubMed]
7. Upadhyay, R.K. Emerging risk biomarkers in cardiovascular diseases and disorders. J. Lipids 2015, 2015. [CrossRef] [PubMed]
8. Lu, X.; Ma, L.; Ruan, L.; Kong, Y.; Mou, H.; Zhang, Z.; Wang, Z.; Wang, J.M.; Le, Y. Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J. Neuroinflamm. 2010, 7, 46. [CrossRef] [PubMed]
9. Catalgol, B.; Batirel, S.; Taga, Y.; Ozer, N.K. Resveratrol: French paradox revisited. Front. Pharmacol. 2012, 3, 141. [CrossRef] [PubMed]
10. Csiszar, A.; Smith, K.; Labinskyy, N.; Orosz, Z.; Rivera, A.; Ungvari, Z. Resveratrol attenuates TNF-alfa-induced activation of coronary arterial endothelial cells: Role of NF-kB inhibition. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H1694-H1699. [CrossRef] [PubMed]
11. Di Castelnuovo, A.; Rotondo, S.; Iacoviello, L.; Donati, M.B.; de Gaetano, G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002, 105, 2836-2844. [CrossRef] [PubMed]
12. Sahebkar, A.; Serban, C.; Ursoniu, S.; Wong, N.D.; Muntner, P.; Graham, I.M.; Mikhailidis, D.P.; Rizzo, M.; Rysz, J.; Sperling, L.S. et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors—Results from a systematic review and meta-analysis of randomized controlled trials. Int. J. Cardiol. 2015, 189, 47-55. [CrossRef] [PubMed]
13. Valdez, R. A simple model-based index of abdominal adiposity. J. Clin. Epidemiol. 1991, 44, 955-956. [CrossRef]
14. Romano, F.; Elkis, H. Translation and adaptation of the Brief Psychiatric Rating Scale-anchored version (BPRS-A). J. Bras. Psiquiatr. 1996, 45, 43-49.
15. De Ligt, M.; Timmers, S.; Schrauwen, P. Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? Biochim. Biophys. Acta 2015, 1852, 1137-1144. [CrossRef] [PubMed]
16. Tomé-Carneiro, J.; Larrosa, M.; González-Sarrías, A.; Tomás-Barberán, F.A.; García-Conesa, M.T.; Espín, J.C. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 19, 6064-6093. [CrossRef] [PubMed]
17. Sahebkar, A. Effects of resveratrol supplementation on plasma lipids: A systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 2013, 71, 822-835. [CrossRef] [PubMed]
18. Qureshi A.A.; Khan D.A.; Mahjabeen, W.; Papasian C J.; Qureshi N. Nutritional Supplement-5 with a Combination of Proteasome Inhibitors (Resveratrol, Quercetin, _-Tocotrienol) Modulate Age-Associated Biomarkers and Cardiovascular Lipid Parameters in Human Subjects. J. Clin. Exp. Cardiol. 2013, 4, 238. [CrossRef] [PubMed]
19. Kjær, T.N.; Poulsen, M.M.; Ornstrup, M.J.; Jørgensen, H.S.; Jørgensen, J.O.; Richelsen, B.; Pedersen, S.B. The antiinflammatory effects of resveratrol: A randomized controlled trial. In Proceedings of the Resveratrol 2014, the 3rd International Conference on Resveratrol and Health, Waikoloa, Hawaii Island, HI, USA, 2014; p.10. Available online: https://www.dropbox.com/s/1frl61xq472iztg/12.12.14-Program_Web.pdf?dl=0 (accessed on 15 January 2015).
20. Liu, K.; Zhou, R.; Wang, B.; Mi, M.T. Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 2014, 99, 1510-1519. [CrossRef] [PubMed]
21. Gurmu, A.E.; Abdela, E.; Allele, B.; Cheru, E.; Amogne, B. Rate of Nonadherence to Antipsychotic Medications and Factors Leading to Nonadherence among Psychiatric Patients in Gondar University Hospital, Northwest Ethiopia. Adv. Psychiatry 2014. [CrossRef]
22. Oksanen, J. Supporting adherence to drug therapy in psychiatry. Duodecim 2015, 131, 1437-1442. [PubMed]
23. Zullig, L.L.; Gellad W.F.; Moaddeb, J.; Crowley, M.J.; Shrank W.; Granger, B.B.; Granger, C.B.; Trygstad, T.; Liu, L.Z.; Bosworth, H.B. Improving diabetes medication adherence: Successful, scalable interventions. Patient Prefer. Adherence 2015, 9, 139-149. [CrossRef] [PubMed]